These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27357245)

  • 1. Predictors of the 10-year direct costs for treating multiple sclerosis.
    Moccia M; Palladino R; Lanzillo R; Triassi M; Brescia Morra V
    Acta Neurol Scand; 2017 May; 135(5):522-528. PubMed ID: 27357245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015.
    Moccia M; Palladino R; Lanzillo R; Carotenuto A; Russo CV; Triassi M; Brescia Morra V
    PLoS One; 2017; 12(1):e0169489. PubMed ID: 28056103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis.
    Ruutiainen J; Viita AM; Hahl J; Sundell J; Nissinen H
    J Med Econ; 2016; 19(1):21-33. PubMed ID: 26360615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
    Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
    J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab treatment for multiple sclerosis in Austria: An observational long-term outcome study.
    Moser T; Foettinger F; Hitzl W; Novotna B; Berger T; Bsteh G; Di Pauli F; Hegen H; Kornek B; Langenscheidt D; Sellner J
    Ann Clin Transl Neurol; 2024 Jun; 11(6):1442-1455. PubMed ID: 38715245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Saccà F; Russo CV; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2018 Jan; 19():50-54. PubMed ID: 29128737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
    J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact on healthcare resource utilization of multiple sclerosis in Spain.
    Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
    BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression.
    Moccia M; Quarantelli M; Lanzillo R; Cocozza S; Carotenuto A; Carotenuto B; Alfano B; Prinster A; Triassi M; Nardone A; Palladino R; Brunetti A; Brescia Morra V
    Eur J Neurol; 2017 Jan; 24(1):195-204. PubMed ID: 27801535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.
    Khakban A; Rodriguez Llorian E; Michaux KD; Patten SB; Traboulsee A; Oh J; Lynd LD;
    Neurology; 2023 Feb; 100(9):e899-e910. PubMed ID: 36450607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis.
    Bozkaya D; Livingston T; Migliaccio-Walle K; Odom T
    J Med Econ; 2017 Mar; 20(3):297-302. PubMed ID: 27822961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis in Italy: cost-of-illness study.
    Patti F; Amato MP; Trojano M; Solaro C; Pappalardo A; Zipoli V; Portaccio E; Paolicelli D; Paolillo A; Mennini FS; Marcellusi A; Ricci C; Battaglia MA
    Neurol Sci; 2011 Oct; 32(5):787-94. PubMed ID: 21409509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term costs for treating multiple sclerosis in a 16-year retrospective cohort study in Brazil.
    Maia Diniz I; Guerra AA; Lovato Pires de Lemos L; Souza KM; Godman B; Bennie M; Wettermark B; de Assis Acurcio F; Alvares J; Gurgel Andrade EI; Leal Cherchiglia M; de Araújo VE
    PLoS One; 2018; 13(6):e0199446. PubMed ID: 29928006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
    Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
    J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.